Comparison of receptor affinity of natSc-DOTA-TATE versus natGa-DOTA-TATE

Nuclear Medicine Review

Volumn 14, Issue 2, 2011, Pages 85-89

  Koumarianou, Eftychia ^a,b   Pawlak, Dariusz ^a   Korsak, Agnieszka ^a   Mikolajczak, Renata ^a  

^a NATIONAL CENTRE FOR NUCLEAR RESEARCH   (Poland)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

DOTA derivatised peptides; Gallium 68; PET tracers; Receptor affinity; Scandium 44

Indexed keywords

DOTA TATE; DOTA TATE GADOLINIUM; DOTA TATE SCANDIUM; GADOLINIUM; OCTREOTIDE; SCANDIUM; SOMATOSTATIN 14; SOMATOSTATIN RECEPTOR 2; TETRAXETAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING COMPETITION; CANCER CELL CULTURE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; ISOTOPE LABELING; MASS SPECTROMETRY; NONHUMAN; PANCREAS CANCER; RAT; RECEPTOR AFFINITY;

ANIMALS; CHELATING AGENTS; GALLIUM RADIOISOTOPES; INHIBITORY CONCENTRATION 50; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RATS; RECEPTORS, SOMATOSTATIN; SCANDIUM; TISSUE DISTRIBUTION;

EID: 84856656820     PISSN: 15069680     EISSN: None     Source Type: Journal    
DOI: 10.5603/NMR.2011.00021     Document Type: Article

References (21)

1. 111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5:42-48.
2. Welch MJ, and McCarthy TJ. The Potential Role of Generator-Produced Radiopharmaceuticals in Clinical PET. J Nucl Med 2000;41:315-317. (Pubitemid 30091353)
3. Rösch F, Knapp FF. Radionuclide generators. In: Vértes A, Nagy S, Klencsár Z, Rösch F (eds). Handbook of nuclear chemistry 2003;4:81-118, Kluver academic Publishers, the Netherlands.
4. edium. Nucl Instrum Methods Phys Res A 2007;571:142-145
5. Mausner LF, Joshi V, Kolsky KL et al. Evaluation of chelating agents for radioimmunotherapy with scandium-47. J Nucl Med 1995;36:104P.
6. 44Sc-based PET-radiopharmaceuticals. Radiochim Acta 2010;98:149-156.
7. 44Sc. J Label Compd Radiopharm 2009;52:S490.
8. NIST Standard Reference Database 46. Critically Selected Stability Constants of Metal Complexes Database. Compiled by: Smith RM, Martell AE, Motekaitis RJ. Version 7.0 for Windows. 2003 US National Institute of Standards and Technology Standard Reference DATA Program; Gaithersburg, MD 20899
9. Polasek M, Kotek J, Hermann P, C sarova I, Binnemans K, Lukes I. Lanthanide(III) complexes of pyridine-N-oxide analogues of DOTA in solution and in the solid state. A new kind of isomerism in complexes of DOTA-like ligands. Inorg Chem 2009;48:466-475.
10. Majkowska-Pilip A, Bilewicz A. Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals J Inorg Biochem 2011;105:313-320.
11. Loncin MF, Desreux JF, Merciny E. Coordination of lanthanides by two polyamino polycarboxylic macrocycles: formation of highly stable lanthanide complexes. Inorg Chem 1986;25:2646-2648
12. Wu SL, Horrocks WD. Direct determination of stability constants of lanthanide ion chelates by laser-excited europium(III) luminescence spectroscopy: application to cyclic and acyclic aminocarboxylate complexes. J Chem Soc Dalton Trans 1997;9:1497-1502. (Pubitemid 127820513)
13. Viola-Villegas N, Doyle RP. The coordination chemistry of 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (H4DOTA): structural overview and analyses on structure-stability relationships. Coordination Chemistry Reviews 2009;253:1906-1925.
14. Prevost G, Marmant C, Gunning M, Thomas F. Therapeutic use and perspectives of synthetic peptides in oncology Acta Oncol 1993;32:209-215. (Pubitemid 23188538)
15. Hofland LJ, Visser-Wisselaar HA, Lamberts SW. Somatostatin analogs: clinical application in relation to human somatostatin receptor subtypes. J Biochem Pharm 1995;50:287-297.
16. Dasgupta P. Somatostatin analogues. Multiple roles in cellular proliferation, neoplacia and angiogenesis. Pharm & Ther 2004;102:61-85. (Pubitemid 38429986)
17. Reubi JC, Schar JC, Waser B et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-282. (Pubitemid 30167697)
18. 177Lu: in vitro and in vivo evaluation. Nucl Med Biol 2009;36:591-603.
19. 177Lu labelled DOTA-Bombesin and its in vitro evaluation in PC-3 cells. Eur J Nucl Med Mol Imaging 2009,36:S309.
20. 177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754-2762.
21. 18F-FDG Cancer 2008;112:2447-2455.